RCEL AVITA Medical, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1762303 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.6%
TTM net income YoY15.3%
TTM EPS YoY18.8%
Revenue 3-yr CAGR31.4%
Net income 3-yr CAGR—
Margins
Gross margin83.7%
Operating margin-58.1%
Net margin-67.1%
FCF margin-51.3%
EBITDA margin-55.7%
Returns
ROE-1,746.3%
ROA-67.1%
ROIC (approx.)-117.7%
Asset turnover1.00x
Leverage & solvency
Liabilities / assets110.5%
Debt / equity—
Current ratio0.67x
Interest coverage-8.33x
Cash quality & payout
Operating cash flow / net income0.70x
Accruals ratio-20.3%
Payout ratio—
Capex / revenue4.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $71.61M | $64.25M | $50.14M | $34.42M | $29.23M |
| Cost of revenue | $12.79M | $9.09M | $7.78M | $6.04M | $5.95M |
| Gross profit | $58.82M | $55.16M | $42.36M | $28.38M | $23.28M |
| R&D expense | $20.84M | $20.36M | $20.82M | $13.86M | $14.82M |
| SG&A expense | $27.37M | $33.20M | $28.33M | $23.33M | $22.40M |
| Operating income | -$42.53M | -$56.59M | -$42.66M | -$27.50M | -$26.54M |
| Interest expense | $5.00M | $5.36M | $1.14M | $16,000 | $22,000 |
| Pretax income | -$48.58M | -$61.79M | -$35.31M | -$26.63M | -$26.55M |
| Income tax | $11,000 | $54,000 | $66,000 | $36,000 | $38,000 |
| Net income | -$48.59M | -$61.84M | -$35.38M | -$26.66M | -$26.58M |
| EBITDA | -$40.19M | -$55.47M | -$42.02M | -$26.94M | -$25.82M |
| EPS (basic) | -1.74 | -2.39 | -1.40 | 1.07 | 1.17 |
| EPS (diluted) | -1.74 | -2.39 | -1.40 | 1.07 | 1.17 |
| Weighted avg. shares (diluted) | 27.86M | 25.88M | 25.33M | 25.00M | 22.67M |
| Banking | |||||
| Provision for credit losses | -$10,000 | $23,000 | $24,000 | -$5,000 | $12,000 |
| Balance sheet | |||||
| Cash & equivalents | $10.24M | $14.05M | $22.12M | $18.16M | $110.75M |
| Short-term investments | $7.94M | $21.84M | $66.94M | $61.18M | — |
| Receivables | $9.09M | $11.80M | $7.66M | $3.52M | $3.47M |
| Inventory | $6.93M | $7.27M | $5.60M | $2.12M | $1.65M |
| Current assets | $35.49M | $57.00M | $104.01M | $87.46M | $121.33M |
| PP&E, net | $8.63M | $10.02M | $1.88M | $1.20M | $1.46M |
| Intangibles | $5.64M | $5.57M | $487,000 | $465,000 | $472,000 |
| Total assets | $56.39M | $79.71M | $111.64M | $98.26M | $125.50M |
| Current liabilities | $62.68M | $20.16M | $13.20M | $10.69M | $7.39M |
| Short-term debt | $42.98M | $0 | — | — | — |
| Long-term debt | $0 | $42.24M | $39.81M | — | — |
| Total debt | $42.98M | $42.24M | $39.81M | — | — |
| Total liabilities | $73.04M | $74.97M | $61.89M | $12.97M | $9.85M |
| Shareholders' equity | -$16.65M | $4.50M | $49.06M | $84.74M | $115.66M |
| Net debt | $32.74M | $28.20M | $17.69M | — | — |
| Shares outstanding | 30.57M | 26.35M | 25.68M | 25.21M | 24.90M |
| Cash flow statement | |||||
| Operating cash flow | -$31.20M | -$48.94M | -$38.01M | -$19.09M | -$25.90M |
| Capital expenditure | $1.00M | $9.17M | $1.38M | $452,000 | $894,000 |
| Free cash flow | -$32.20M | -$58.11M | -$39.39M | -$19.54M | -$26.80M |
| Investing cash flow | $12.45M | $37.36M | $1.61M | -$19.33M | -$1.17M |
| Financing cash flow | $14.94M | $3.51M | $40.37M | $900,000 | $64.05M |
| Depreciation & amortization | $2.35M | $1.13M | $632,000 | $568,000 | $715,000 |
| Stock-based compensation | $9.52M | $13.50M | $8.38M | $7.00M | $5.66M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.